The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil

  • Authors:
    • Kinya Matsuoka
    • Kazunori Tsukuda
    • Manabu Suda
    • Kazuyasu Kobayashi
    • Tetsuya Ota
    • Atsushi Okita
    • Keitaro Watanabe
    • Eiji Suzuki
    • Masakazu Murakami
    • Hiroyoshi Doihara
    • Nobuyoshi Shimizu
  • View Affiliations

  • Published online on: January 1, 2004     https://doi.org/10.3892/ijo.24.1.217
  • Pages: 217-222
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

5-Fluorouracil (5-FU), a fluoropyrimidine analogue, is one of the most commonly used anticancer drugs for the treatment of gastrointestinal malignancies. Some studies reported that the cytotoxicity of fluoropyrimidines is mediated, in large part, by inhibition of the thymidylate synthase (TS), an essential DNA synthetic enzyme. The aim of this study was to determine if antisense TS technology could augment the chemosensitivity of human cancer cells to 5-FU. The full length coding region of TS cDNA was inversely cloned into the eukaryotic expression vector pCDL81 and transfected into DLD-1 cells. The expression and activity of TS were significantly suppressed in the antisense TS transfected cells. Interestingly, the transfection of antisense TS alone inhibited the cellular growth in vitro. The chemosensitivity to 5-FU was significantly increased in the transfected cells. The 50% inhibition values of 5-FU on DLD-1/anti-TS were approximately one forth that on parental cells. The augmentation of chemosensitivity to 5-FU was also confirmed in a nude mice model. The tumor growth of DLD-1/anti-TS cells was suppressed significantly more than that of DLD-1 cells by the 5-FU. The expression and activity of TS in human colon cancer cells were effectively inhibited by TS antisense treatment and the effect of 5-FU to cancer cells can be augmented. The antisense TS technology could be promising for treatments of gastrointestinal cancers.

Related Articles

Journal Cover

January 2004
Volume 24 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Matsuoka, K., Tsukuda, K., Suda, M., Kobayashi, K., Ota, T., Okita, A. ... Shimizu, N. (2004). The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil. International Journal of Oncology, 24, 217-222. https://doi.org/10.3892/ijo.24.1.217
MLA
Matsuoka, K., Tsukuda, K., Suda, M., Kobayashi, K., Ota, T., Okita, A., Watanabe, K., Suzuki, E., Murakami, M., Doihara, H., Shimizu, N."The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil". International Journal of Oncology 24.1 (2004): 217-222.
Chicago
Matsuoka, K., Tsukuda, K., Suda, M., Kobayashi, K., Ota, T., Okita, A., Watanabe, K., Suzuki, E., Murakami, M., Doihara, H., Shimizu, N."The transfection of thymidylate synthase antisense suppresses oncogenic properties of a human colon cancer cell line and augments the antitumor effect of fluorouracil". International Journal of Oncology 24, no. 1 (2004): 217-222. https://doi.org/10.3892/ijo.24.1.217